Clinical trials: Sintilimab
Advanced Renal Cell Carcinoma
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
The study consists of two parts, the first part is a randomized, open-label, active-controlled study to evaluate the efficacy and safety of fruquintinib in combination with sintilimab versus axitinib or everolimus monotherapy as…
- Trial name
- NCT05522231
- Testing
- fruquintinib+sintilimab, axitinib / everolimus, fruquintinib
- Where
- 48 sites in China
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Sintilimab, Lung Cancer
Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC
primary purpose：Observe the pathological complete response rate (PCR) of postoperative tumor tissue resection and evaluate the safety of the treatment process.
- Conditions
- Sintilimab, Lung Cancer, Anlotinib, Chemotherapy
- Trial name
- NCT05400070
- Testing
- Neoadjuvant therapy 1
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tang-Du Hospital
Healthy Male Subjects
Phase I Study of Sintilimab in Healthy Chinese Male Subjects
The purpose of this study is to evaluate the pharmacokinetic similarity of sintilimab with different manufacturing process in healthy male subjects.
- Trial name
- NCT05337267
- Testing
- sintilimab (after the change), sintilimab (before the change)
- Where
- China
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.